Second Brazilian Consensus Conference On Helicobacter Pylori Infection [ii Consenso Brasileiro Sobre Helicobacter Pylori]

Significant progress has been obtained since the First Brazilian Consensus Conference on H. pylori Infection held in 1995, in Belo Horizonte, MG, and justify a second meeting to establish updated guidelines on the current management of H. pylori infection. The Second Brazilian Consensus Conference on H. pylori Infection was organized by the Brazilian Federation of Gastroenterology and Brazilian Nucleus for the Study of Helicobacter and took place on June, 19-20, 2004 in São Paulo, SP. Thirty six delegates coming from 15 different Brazilian states including gastroenterologists, pathologists, microbiologists and pediatricians undertook the meeting. The participants were allocated in one the five main topics of the meeting: H. pylori and dyspepsia, H. pylori and NSAIDs, H. pylori and gastroesophageal reflux disease, H. pylori treatment, and H. pylori retreatment. Seventy per cent and more votes were considered as acceptance for the final statement. The results were presented during a special session on the VI Brazilian Week of Digestive System, in Recife, PE (October 2004), and this publication represents the summary of the main recommendations and conclusions emerged from the meeting.422128132Coelho, L.G., León-Barúa, R., Quigley, E.M., Latin-American Consensus Conference on Helicobacter pylori Infection (2000) Am J Gastroenterol, 95, pp. 2688-2691Coelho, L.G.V., Barros, C.A.S., Lima, D.C.A., Barbosa, A.J.A., Magalães, A.F.N., Oliveira, C.A., Queiroz, D.M.M., Zaterka, S., Consenso Nacional sobre H. pylori e afecções associadas (1996) GED Gastroenterol Endosc Dig, 15, pp. 53-58Coelho, L.G.V., Mattos, A.A., Francisconi, C.F.M., Castro, L.P., André, S.B., Eficácia do regime terapêutico empregando a associação de pantoprazol, claritromicina e amoxicilina, durante uma semana, na erradicação do Helicobacter pylori em pacientes com úlcera péptica (2004) Arq Gastroenterol, 41, pp. 71-76Coelho, L.G.V., Moretzsohn, L.D., Vieira, W.L.S., Gallo, M.A., Passos, M.C.F., Cindr, J.M., Cerqueira, M.C., Castro, L.P., New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures. A pilot study (2005) Aliment Pharmacol Ther, 21, pp. 783-787Current European Concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report (1997) Gut, 41, pp. 8-13Dani, R., Queiroz, D.M., Dias, M.G., Franco, J.M., Magalhães, L.C., Mendes, G.S., Moreira, L.S., Salles, P.G., Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer (1999) Aliment Pharmacol Ther, 13, pp. 1647-1652Graham, D.Y., Belson, G., Abudayyeh, S., Osato, M.S., El-Zimaity, H.M.T., Dore, M.P., Twice a day (mid-day and evening), quadruple therapy for H. pylori in the United States (2004) Dig Liver Dis, 36, pp. 377-379Janowitz, H.D., Abittan, C.S., Fiedler, L.M., A gastroenterological list for the millennium (1999) J Clin Gastroenterol, 29, pp. 336-338Kawakami, E., Ogata, S.K., Portorreal, A.C., Magni, A.M., Pardo, M.L., Patrício, F.R., Triple therapy with clarithromycin, amoxicillin and omeprazole for Helicobacter pylori eradication in children and adolescents (2001) Arq Gastroenterol, 38, pp. 203-206Lam, S.K., Talley, N.J., Helicobacter pylori Consensus. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection (1998) J Gastroenterol Hepatol, 13, pp. 1-12Magalhaes, A.F., Macedo, C., Hauck, J.R., Carvalhaes, A., De Nucci, G., Magna, L.A., Pedrazzoli, J., Acid suppression with ranitidine plus oral triple therapy improves ulcer healing but not Helicobacter pylori eradication (1998) Hepatogastroenterology, 45, pp. 2161-2164Malfertheiner, P., Mégraud, F., O'Morain, C., Hungin, A.P., Jones, R., Axon, A., Graham, D.Y., Tytgat, G., Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report (2002) Aliment Pharmacol Ther, 16, pp. 167-180Marshall, B.J., Warren, J.R., Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration (1984) Lancet, 1, pp. 1311-1315Mazzoleni, L.E., (2003) Beneficio Sintomatico em População de Pacientes com Dispepsia Funcional Após a Erradicação do Helicobacter Pylori: Resultado de Estudo de 12 Meses, Randomizado, Duplo-cego, Controlado com Placebo, , [tese]. Porto Alegre: Universidade Federal do Rio Grande do SulHelicobacter pylori in peptic ulcer disease (1994) JAMA, 272, pp. 65-69Nista, E.C., Candelli, M., Cremonini, F., Cazzato, I.A., Di Caro, S., Gabrielli, M., Santarelli, L., Gasbarrini, A., Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: A randomized trial (2003) Aliment Pharmacol Ther, 18, pp. 627-633Orsi, P., Pinazzi, O., Aragona, G., Di Mario, F., Rabeprazol/levofloxacin based triple therapy as a salvatage treatment after failure of H. pylori eradication with standard regimens (2003) Helicobacter, 8, pp. 463-464Passes, M.C.F., (1999) Ensaio Prospective, Randomizado, Duplo Cego, Placebo-controlado do Efeito da Erradicação do Helicobacter Pylori nos Pacientes Dispépticos Funcionais, , [dissertação]. Belo Horizonte: Universidade Federal de Minas GeraisPinheiro, J.O.P., Both, C.T., Dietrich, S., Zamin, J.I., Raymondi, R.P., Muretti, I., Mattos, A.A., Tratamento do Helicobacter pylori: Comparação de dois esquemas terapêuticos (1999) GED Gastroenterol Endosc Dig, 18, pp. 97-101Sherwood, L.G., Bismuth therapy in gastrointestinal disease (1990) Gastroenterology, 99, pp. 863-875Silva, F.M., Eisig, J.N., Chehter, E.Z., Silva, J.J., Laudanna, A.A., Omeprazole, furazolidone, and tetracycline: An eradication treatment for resistant H. pylori in Brazilian patients with peptic ulcer disease (2002) Rev Hosp Clin Fac Med São Paulo, 57, pp. 205-208Talley, N.J., Stanghellini, V., Heading, R.C., Koch, K.L., Malagelada, J.R., Tytgat, G.N.J., Functional gastroduodenal disorders (2000) Rome II: The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology, and Treatment: A Multinational Consensus. 2 nd Ed., pp. 299-350. , Drossman DA, Corazziari E, Talley NJ, Thompson G, Whitehead WE, editors. McLean, Virginia. Degnon AssociatesTytgat, G.N.T., (1990) Working Party Report of the World Congress of Gastroenterology. Helicobacter Pylori: Causal Agent in Peptic Ulcer Disease?, , Sydney, AustraliaVieira, W.L.S., Coelho, L.G.V., Castro, F.J., Passos, M.C.F., Franco, J.M.M., Moretzsohn, L.D., Trindade, O.R., Castro, L.P., Terapia tripla com lansoprazol, claritromicina e amoxicilina, por dez dias, na erradicação do Helicobacter pylori em pacientes com ulcera duodenal (2001) GED Gastroenterol Endosopia Digestiva, 20, pp. 201-207Vieira, W.L.S., (2002) Retratamento da Infecção pelo Helicobacter Pylori em Pacientes Portadores de Úlcra Duodenal e Seguimento a Longo Prazo. Ensaio Clínico, Aberto, Prospective e Randomizado Com Dosagens Séricas e Urinárias de Antimicrobianos, , [tese]. Belo Horizonte: Universidade Federal de Minas GeraisZullo, A., Hassan, C., De Francesco, V., Lorenzetti, R., Marignani, M., Angeletti, S., Ierardi, E., Morini, S., A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication (2003) Dig Liver Dis, 35, pp. 232-23

Application of isotope-selective non-dispersive infrared spectrometry for the evaluation of the 13C-urea breath test: comparison with three concordant methods

The aim of this work was to compare the performance of isotope-selective non-dispersive infrared spectrometry (IRIS) for the 13C-urea breath test with the combination of the 14C-urea breath test (14C-UBT), urease test and histologic examination for the diagnosis of H. pylori (HP) infection. Fifty-three duodenal ulcer patients were studied. All patients were submitted to gastroscopy to detect HP by the urease test, histologic examination and 14C-UBT. To be included in the study the results of the 3 tests had to be concordant. Within one month after admission to the study the patients were submitted to IRIS with breath samples collected before and 30 min after the ingestion of 75 mg 13C-urea dissolved in 200 ml of orange juice. The samples were mailed and analyzed 11.5 (4-21) days after collection. Data were analyzed statistically by the chi-square and Mann-Whitney test and by the Spearman correlation coefficient. Twenty-six patients were HP positive and 27 negative. There was 100% agreement between the IRIS results and the HP status determined by the other three methods. Using a cutoff value of delta-over-baseline (DOB) above 4.0 the IRIS showed a mean value of 19.38 (minimum = 4.2, maximum = 41.3, SD = 10.9) for HP-positive patients and a mean value of 0.88 (minimum = 0.10, maximum = 2.5, SD = 0.71) for negative patients. Using a cutoff value corresponding to 0.800% CO2/weight (kg), the 14C-UBT showed a mean value of 2.78 (minimum = 0.89, maximum = 5.22, SD = 1.18) in HP-positive patients. HP-negative patients showed a mean value of 0.37 (minimum = 0.13, maximum = 0.77, SD = 0.17). IRIS is a low-cost, easy to manage, highly sensitive and specific test for H. pylori detection. Storing and mailing the samples did not interfere with the performance of the test

Application of isotope-selective non-dispersive infrared spectrometry for the evaluation of the 13C-urea breath test: comparison with three concordant methods

The aim of this work was to compare the performance of isotope-selective non-dispersive infrared spectrometry (IRIS) for the 13C-urea breath test with the combination of the 14C-urea breath test (14C-UBT), urease test and histologic examination for the diagnosis of H. pylori (HP) infection. Fifty-three duodenal ulcer patients were studied. All patients were submitted to gastroscopy to detect HP by the urease test, histologic examination and 14C-UBT. To be included in the study the results of the 3 tests had to be concordant. Within one month after admission to the study the patients were submitted to IRIS with breath samples collected before and 30 min after the ingestion of 75 mg 13C-urea dissolved in 200 ml of orange juice. The samples were mailed and analyzed 11.5 (4-21) days after collection. Data were analyzed statistically by the chi-square and Mann-Whitney test and by the Spearman correlation coefficient. Twenty-six patients were HP positive and 27 negative. There was 100% agreement between the IRIS results and the HP status determined by the other three methods. Using a cutoff value of delta-over-baseline (DOB) above 4.0 the IRIS showed a mean value of 19.38 (minimum = 4.2, maximum = 41.3, SD = 10.9) for HP-positive patients and a mean value of 0.88 (minimum = 0.10, maximum = 2.5, SD = 0.71) for negative patients. Using a cutoff value corresponding to 0.800% CO2/weight (kg), the 14C-UBT showed a mean value of 2.78 (minimum = 0.89, maximum = 5.22, SD = 1.18) in HP-positive patients. HP-negative patients showed a mean value of 0.37 (minimum = 0.13, maximum = 0.77, SD = 0.17). IRIS is a low-cost, easy to manage, highly sensitive and specific test for H. pylori detection. Storing and mailing the samples did not interfere with the performance of the test